


What is claimed is:

1. A hemitartrate tetrahydrate of [5-(4,6-Dimethyl-1H-benzimidazol-2-yl)-4-methyl-pyrimidin-2-yl]-[3-(1-methyl-piperidin-4-yl)-propyl]-amine of formula:



2. A hemitartrate tetrahydrate according to claim 1, wherein the X-ray diffraction profile of said hemitartrate tetrahydrate comprises the following peaks:

Position [°2θ]	d-spacing [Å]	Intensity (counts)	Relative Intensity (%)
8.692	10.17	92032	100.0
12.107	7.31	51083	55.5
21.734	4.09	79383	86.3
24.352	3.66	48026	52.2.

3. A hemitartrate tetrahydrate according to claim 1, wherein the X-ray diffraction profile of said hemitartrate tetrahydrate comprises the following peaks:

Position [°2θ]	d-spacing [Å]	Intensity (counts)	Relative Intensity (%)
6.909	12.79	19018	20.7
8.692	10.17	92032	100.0
12.107	7.31	51083	55.5
19.265	4.61	23648	25.7
21.734	4.09	79383	86.3
24.052	3.70	28743	31.2
24.352	3.66	48026	52.2.

4. A hemitartrate tetrahydrate according to claim 1, wherein the X-ray diffraction profile of said hemitartrate tetrahydrate comprises the following peaks:

Position [°2 θ]	d-spacing [Å]	Intensity (counts)	Relative Intensity (%)
6.909	12.79	19018	20.7
6.963	12.70	13509	14.7
8.692	10.17	92032	100.0
12.107	7.31	51083	55.5
16.304	5.44	15526	16.9
16.350	5.42	14203	15.4
19.265	4.61	23648	25.7
21.734	4.09	79383	86.3
23.963	3.71	11967	13.0
24.052	3.70	28743	31.2
24.352	3.66	48026	52.2

Position [°2 θ]	d-spacing [Å]	Intensity (counts)	Relative Intensity (%)
25.124	3.54	12475	13.6
27.012	3.30	13716	14.9


5. A hemitartrate tetrahydrate according to claim 1, wherein the X-ray diffraction profile of said hemitartrate tetrahydrate comprises the following peaks:

Position [°2 θ]	d-spacing [Å]	Intensity (counts)	Relative Intensity (%)
6.909	12.79	19018	20.7
6.963	12.70	13509	14.7
8.692	10.17	92032	100.0
12.107	7.31	51083	55.5
16.304	5.44	15526	16.9
16.350	5.42	14203	15.4
19.265	4.61	23648	25.7
19.861	4.47	10731	11.7
19.906	4.46	10331	11.2
21.628	4.11	10197	11.1
21.734	4.09	79383	86.3
23.963	3.71	11967	13.0
24.052	3.70	28743	31.2
24.352	3.66	48026	52.2
25.124	3.54	12475	13.6
27.012	3.30	13716	14.9




6. A hemitartrate tetrahydrate according to claim 1, wherein the X-ray diffraction profile of said hemitartrate tetrahydrate comprises the following peaks:

Position [°2 θ]	d-spacing [Å]	Intensity (counts)	Relative Intensity (%)
6.909	12.79	19018	20.7
6.963	12.70	13509	14.7
8.692	10.17	92032	100.0
11.957	7.40	5763	6.3
12.107	7.31	51083	55.5
12.419	7.13	6894	7.5
13.956	6.35	5038	5.5
14.463	6.12	6922	7.5
15.355	5.77	6205	6.7
15.393	5.76	5573	6.1
15.755	5.62	4416	4.8
16.304	5.44	15526	16.9
16.350	5.42	14203	15.4
17.051	5.20	6303	6.8
17.442	5.08	5085	5.5
18.445	4.81	7903	8.6
18.540	4.79	5021	5.5
19.265	4.61	23648	25.7
19.861	4.47	10731	11.7
19.906	4.46	10331	11.2
21.628	4.11	10197	11.1
21.734	4.09	79383	86.3
22.514	3.95	8529	9.3
23.115	3.85	4787	5.2
23.963	3.71	11967	13.0
24.052	3.70	28743	31.2
24.352	3.66	48026	52.2
25.124	3.54	12475	13.6
26.434	3.37	8095	8.8
27.012	3.30	13716	14.9
30.257	2.95	5159	5.6
30.297	2.95	6434	7.0
30.449	2.94	7306	7.9


7. A hemitartrate tetrahydrate of [5-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methyl-pyrimidin-2-yl]-[3-(1-methyl-piperidin-4-yl)-propyl]-amine of formula:




wherein said hemitartrate tetrahydrate is substantially free of at least impurities I1, I3 and I8 of formulae:



8. A hemitartrate tetrahydrate of [5-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methyl-pyrimidin-2-yl]-[3-(1-methyl-piperidin-4-yl)-propyl]-amine according to claim 7, wherein said hemitartrate tetrahydrate is further substantially free of at least impurity I5 of formula:



9. A hemitartrate tetrahydrate of [5-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methyl-pyrimidin-2-yl]-[3-(1-methyl-piperidin-4-yl)-propyl]-amine according to claim 8, wherein said hemitartrate tetrahydrate does not contain more than about 0.2% of impurity I7 of formula:



10. A hemitartrate tetrahydrate of [5-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methyl-pyrimidin-2-yl]-[3-(1-methyl-piperidin-4-yl)-propyl]-amine according to claim 9, wherein said hemitartrate tetrahydrate does not contain more than about 0.06% of impurity I7 of formula:

